

Massimiliano Calabrese

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4005833/massimiliano-calabrese-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142
papers

6,266
citations

46
h-index

77
g-index

162
ext. papers

7,505
ext. citations

5.5
avg, IF

5.56
L-index

#	Paper	IF	Citations
142	Slowing processing speed is associated with cognitive fatigue in newly diagnosed multiple sclerosis patients.. <i>Journal of the International Neuropsychological Society</i> , 2022 , 1-7	3.1	0
141	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021 ,	6	1
140	Coping Strategies and Their Impact on Quality of Life and Physical Disability of People with Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
139	Social Cognition in Multiple Sclerosis: A 3-Year Follow-Up MRI and Behavioral Study. <i>Diagnostics</i> , 2021 , 11,	3.8	3
138	Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. <i>Current Opinion in Neurology</i> , 2021 , 34, 277-285	7.1	0
137	A Videogame-Based Approach to Measuring Information Processing Speed in Multiple Sclerosis Patients. <i>Games for Health Journal</i> , 2021 , 10, 115-120	4.2	1
136	2021 ,		1
135	Repeated passive mobilization to stimulate vascular function in individuals of advanced age who are chronically bedridden. A randomized controlled trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 ,	6.4	2
134	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021 , 424, 117430	3.2	
133	A novel prognostic score to assess the risk of progression in relapsing-remitting multiple sclerosis patients. <i>European Journal of Neurology</i> , 2021 , 28, 2503-2512	6	3
132	Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211018987	5	5
131	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. <i>Brain</i> , 2021 , 144, 1296-1311	11.2	12
130	Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing-Remitting Multiple Sclerosis Phenotypes. <i>Journal of Magnetic Resonance Imaging</i> , 2021 ,	5.6	2
129	Interpretable deep learning as a means for decrypting disease signature in multiple sclerosis. <i>Journal of Neural Engineering</i> , 2021 , 18,	5	2
128	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021 , 89, 13-23	9.4	38
127	Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis. <i>Lecture Notes in Computer Science</i> , 2021 , 70-79	0.9	1
126	Explainable 3D-CNN for Multiple Sclerosis Patients Stratification. <i>Lecture Notes in Computer Science</i> , 2021 , 103-114	0.9	

125	CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 534-547	5.3	4
124	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 780-789	9.4	189
123	Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211032510	5	2
122	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035318	5	21
121	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1738-1744	5.3	36
120	Artery of Percheron stroke from carotid lesion. <i>Neurological Sciences</i> , 2021 , 42, 4807-4808	3.5	
119	Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211031786	5	1
118	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	13
117	CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021 , 8,	9.1	3
116	Imaging and depression in multiple sclerosis: a historical perspective. <i>Neurological Sciences</i> , 2021 , 42, 835-845	3.5	1
115	The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. <i>Annals of Neurology</i> , 2020 , 88, 562-573	9.4	22
114	Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102372	4	21
113	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020 , 41, 2249-2253	3.5	
112	The Vascular Side of Chronic Bed Rest: When a Therapeutic Approach Becomes Deleterious. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
111	Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 511-516	3.8	5
110	Executive functioning affects verbal learning process in multiple sclerosis patients: Behavioural and imaging results. <i>Journal of Neuropsychology</i> , 2020 , 14, 384-398	2.6	3
109	Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients. <i>Frontiers in Cellular Neuroscience</i> , 2020 , 14, 569827	6.1	2
108	Visual-Attentional Load Unveils Slowed Processing Speed in Multiple Sclerosis Patients: A Pilot Study with a Tablet-Based Videogame. <i>Brain Sciences</i> , 2020 , 10,	3.4	3

107	The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>Diagnostics</i> , 2020 , 10,	3.8	8
106	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirms group. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102394	4	1
105	The BAFF / APRIL system as therapeutic target in multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 1135-1145	6.4	7
104	False memories in relapsing remitting multiple sclerosis patients: A preliminary investigation with the DRM paradigm. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101418	4	
103	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101461	4	8
102	Social cognition deficits and the role of amygdala in relapsing remitting multiple sclerosis patients without cognitive impairment. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 29, 118-123	4	26
101	"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. <i>Neurology</i> , 2019 , 92, e2527-e2537	6.5	22
100	Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study. <i>Frontiers in Immunology</i> , 2019 , 10, 1666	8.4	10
99	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 1446-1456	17.2	59
98	Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2150-2163	5.3	28
97	Increase of CSF inflammatory profile in a case of highly active multiple sclerosis. <i>BMC Neurology</i> , 2019 , 19, 231	3.1	7
96	Lost in Classification: Lower Cognitive Functioning in Apparently Cognitive Normal Newly Diagnosed RRMS Patients. <i>Brain Sciences</i> , 2019 , 9,	3.4	9
95	Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis. <i>BMJ Open</i> , 2019 , 9, e030469	3	6
94	Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 305-311	4	4
93	Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. <i>Annals of Neurology</i> , 2018 , 83, 739-755	9.4	129
92	Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 387-395	4	15
91	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. <i>NeuroImage: Clinical</i> , 2018 , 19, 466-475	5.3	33
90	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018 , 265, 1174-1183	5.5	18

89	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 316-318	5.5	14
88	MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course. <i>Brain Pathology</i> , 2018 , 28, 735-742	6	23
87	The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. <i>Neurology</i> , 2018 , 90, e2107-e2118	6.5	51
86	The effect of fingolimod on focal and diffuse grey matter damage in active MS patients. <i>Journal of Neurology</i> , 2018 , 265, 2154-2161	5.5	7
85	Epilepsy in multiple sclerosis: The role of temporal lobe damage. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 473-482	5	21
84	Cortical Gray Matter MR Imaging in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017 , 27, 301-312	3	21
83	QTc interval in patients with multiple sclerosis: an inference from the insula of Reil?. <i>European Journal of Neurology</i> , 2017 , 24, 491-496	6	7
82	Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. <i>Journal of Neuroinflammation</i> , 2017 , 14, 40	10.1	49
81	Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1087-1095	4.4	8
80	A case of epilepsy in multiple sclerosis: Three-dimensional double inversion recovery sequences revealed cortical dysplasia. <i>Neuroradiology Journal</i> , 2017 , 30, 352-355	2	3
79	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017 , 264, 973-978	5.5	13
78	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. <i>Journal of Neurology</i> , 2017 , 264, 2420-2430	5.5	88
77	Response to Nagai et al. <i>European Journal of Neurology</i> , 2017 , 24, e54	6	
76	A case of acute fulminant multiple sclerosis treated with alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 9-11	4	11
75	Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 848-854	5	59
74	Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 1073-1078	5.5	10
73	Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. <i>Neurology</i> , 2016 , 87, 2463-2470	6.5	40
72	Assessing response to interferon-β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016 , 87, 134-40	6.5	74

71	Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 580-9	5	18
70	Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11974-83	5.6	66
69	Exploring the origins of grey matter damage in multiple sclerosis. <i>Nature Reviews Neuroscience</i> , 2015 , 16, 147-58	13.5	250
68	Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015 , 10, e0135428	3.7	39
67	Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 1417-28	4.3	5
66	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1265-8	5	9
65	Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: yes. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 537-8	5	7
64	Automatic Segmentation of Gray Matter Multiple Sclerosis Lesions on DIR Images. <i>IFMBE Proceedings</i> , 2014 , 241-244	0.2	2
63	Low degree of cortical pathology is associated with benign course of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 904-11	5	30
62	Grey matter lesions in MS: from histology to clinical implications. <i>Prion</i> , 2013 , 7, 20-7	2.3	39
61	Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 457-63	7.3	30
60	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. <i>Neurological Sciences</i> , 2013 , 34, 197-203	3.5	2
59	Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. <i>Disease Markers</i> , 2013 , 35, 687-99	3.2	55
58	Increased incidence of multiple sclerosis in the Veneto region, Italy. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 601-4	5	16
57	The changing clinical course of multiple sclerosis: a matter of gray matter. <i>Annals of Neurology</i> , 2013 , 74, 76-83	9.4	55
56	Anatomical correlates of cognitive functions in early Parkinson's disease patients. <i>PLoS ONE</i> , 2013 , 8, e64222	3.7	42
55	Measurement and clinical effect of grey matter pathology in multiple sclerosis. <i>Lancet Neurology</i> , 2012 , 11, 1082-92	24.1	213
54	No MRI evidence of cortical lesions in neuromyelitis optica. <i>Neurology</i> , 2012 , 79, 1671-6	6.5	91

53	Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1640-3	5	72
52	Cortical lesion load associates with progression of disability in multiple sclerosis. <i>Brain</i> , 2012 , 135, 2952-61.2	61.2	191
51	The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 174-80	5	18
50	Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 418-24	5	58
49	Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 49-54	5.5	54
48	Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1507-11	4.4	19
47	Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1760-7	5	33
46	Cortical Pathology in RRMS: Taking a Cue from Four Sisters. <i>Multiple Sclerosis International</i> , 2012 , 2012, 760254	1.1	2
45	Supervised classification of brain tissues through local multi-scale texture analysis by coupling DIR and FLAIR MR sequences 2012 ,		3
44	Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. <i>PLoS ONE</i> , 2011 , 6, e26712	3.7	10
43	Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. <i>Neurological Sciences</i> , 2011 , 31 Suppl 3, 317-20	3.5	5
42	No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. <i>Annals of Neurology</i> , 2011 , 69, 90-9	9.4	119
41	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. <i>Neurology</i> , 2011 , 76, 418-24	6.5	212
40	Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. <i>Neurology</i> , 2011 , 77, 844-50	6.5	52
39	The puzzle of multiple sclerosis: gray matter finds its place. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1565-8	4.3	5
38	Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study. <i>Radiology</i> , 2011 , 261, 891-8	20.5	70
37	Cortical pathology and cognitive impairment in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 425-32	4.3	59
36	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 319-26	5	8

35	The predictive value of gray matter atrophy in clinically isolated syndromes. <i>Neurology</i> , 2011 , 77, 257-636.5	122
34	Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1988-94	6.5 134
33	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. <i>Neurology</i> , 2010 , 74, 1868-76	6.5 234
32	No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1345-50	5.5 23
31	Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1220-8	5 154
30	Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. <i>Neurology</i> , 2010 , 74, 321-8	6.5 118
29	Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1234-40	6.5 66
28	Cortical lesions in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010 , 6, 438-44	15 179
27	Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 401-4	5.5 51
26	A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 67, 376-83	9.4 118
25	Cortical lesions and cognitive impairment in multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S235-7	3.5 30
24	Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 363-70	5 68
23	Magnetic resonance evidence of cortical onset of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 933-41	5 61
22	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 36-41	5 64
21	Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. <i>Neurology</i> , 2009 , 72, 1330-6	6.5 108
20	Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1359-62	5 15
19	MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. <i>Neurology</i> , 2009 , 72, 1693-701	6.5 43
18	Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 1144-50	359

17	Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S171-3	3.5	66
16	Investigation of the neural correlates underlying action observation in multiple sclerosis patients. <i>Experimental Neurology</i> , 2009 , 217, 252-7	5.7	7
15	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. <i>NeuroImage</i> , 2008 , 42, 1324-8	7.9	51
14	Cyclophosphamide-based combination therapies for autoimmunity. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S233-4	3.5	13
13	Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. <i>Journal of Neurology</i> , 2008 , 255, 581-6	5.5	102
12	Cortical atrophy is relevant in multiple sclerosis at clinical onset. <i>Journal of Neurology</i> , 2007 , 254, 1212-20	5	182
11	The safety profile of cyclophosphamide in multiple sclerosis therapy. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 183-90	4.1	51
10	Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 1416-22		249
9	Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. <i>Brain</i> , 2006 , 129, 1993-2007	11.2	34
8	Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 953-5	5.5	43
7	Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. <i>Journal of Neurology</i> , 2006 , 253, 636-9	5.5	34
6	Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. <i>Journal of Neurology</i> , 2006 , 253, 1034-40	5.5	19
5	In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2006 , 27, 2161-7	4.4	56
4	The clinical impact of interferon beta antibodies in relapsing-remitting MS. <i>Journal of Neurology</i> , 2004 , 251, 305-9	5.5	85
3	Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 387-92	5	56
2	Cerebrospinal fluid examination in the differential diagnosis of inflammatory myelopathies. <i>Neurological Sciences</i> , 2001 , 22 Suppl 2, S65-8	3.5	6
1	Cognition and fatigue in multiple sclerosis. 127-148		2